A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008
Phase of Trial: Phase I/II
Latest Information Update: 07 Sep 2017
At a glance
- Drugs LY 2780301 (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TAKTIC
- 01 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated
- 08 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.